Your new post is loading...
A medical team, including a researcher at the University of Alberta, has identified a biomarker able to predict which prostate cancer patients are more likely to have serious, quicker recurrences of the disease.
|
Scooped by Graham Player Ph.D. |
Scoop.it!
No comment yet.
Sign up to comment
John Lewis, a cancer researcher in the faculty of medicine at the U of Alberta, said he and a team from Vanderbilt University in Nashville, Tenn., have discovered an antibody that, when added to a biopsy sample taken from a man with prostate cancer, sticks only to certain proteins that metastasize or spread the cancer through the body.
The men who carry the mutating CD151 protein — the biomarker of more aggressive prostate cancer — are likely to have a recurrence of the cancer in four years, rather than the usual 15 to 20 years, since most prostate cancer grows slowly, Lewis said.